As medicine continues to advance, some patients still face exceptionally complex treatment challenges — including those with relapsed or refractory hematologic malignancies, advanced solid tumors, and chronic, relapsing, and difficult-to-control autoimmune diseases such as systemic lupus erythematosus (SLE). For these patients, conventional therapies often fail to provide durable disease control, and treatment options remain limited.

Around 2013, following landmark cases such as Emily's widely reported response to CAR-T therapy, cell therapy began attracting global attention as an entirely new therapeutic approach with a distinct mechanism of action. Over the past decade, cell therapy has gradually moved from early exploration into broader clinical application, with its clinical value continuously validated and expanded.

At the same time, however, a more practical question has emerged: once the technology itself becomes available, how can this treatment truly be delivered well?

 

 

When Cell Therapy Is Already Available, What Is the Real Question?

For many patients, the first question is often: “Should I try this new technology?”

But once treatment begins, that question quickly evolves into something far more practical: “How can this treatment actually be done well?”

As more CAR-T products enter clinical use, technology itself is no longer the only factor patients need to consider. Differences in clinical experience, risk management, management of complex cases, and long-term follow-up capabilities between medical teams are becoming increasingly apparent.

As a result, more patients are beginning to focus on questions such as: Who is delivering this treatment? Has the team managed large-scale real-world clinical cases? Do they have experience handling complex complications? These factors often directly shape the entire treatment journey that follows.

 

Is Cell Therapy a Single Procedure — or a Long-Term Treatment Journey?

In many people's minds, cell therapy — particularly CAR-T therapy — may appear to be simply a single cell infusion. In reality, however, the infusion is only one part of a much longer treatment process.

The process begins with comprehensive patient evaluation, including assessment of disease status, progression, and prior therapies to determine whether the patient is suitable for this treatment pathway. This is followed by treatment planning, dynamic adjustments, cell collection and manufacturing, and ultimately infusion.

After infusion, patients may experience fever, cytokine release syndrome (CRS), neurotoxicity (ICANS), infections, immune recovery challenges, and other complications. Long-term follow-up is also required to evaluate response and recovery.

These stages are closely interconnected and rarely function independently. For patients, cell therapy is not simply a procedure, but an ongoing treatment journey. What ultimately determines outcomes is often not the infusion day itself, but the entire process surrounding it.

The ability to manage this full treatment journey is not built overnight. It depends on long-term accumulation through large-scale clinical practice. To date, GoBroad Healthcare Group has completed more than 5,000 CAR-T treatments across leukemia, lymphoma, multiple myeloma, autoimmune diseases, and solid tumors. This extensive clinical experience has enabled the team to gradually establish a more mature and comprehensive management framework covering the entire treatment pathway.

 

If the Technology Is Similar, Why Do Patient Outcomes Differ?

As more patients receive CAR-T and other forms of cell therapy, one reality has become increasingly clear: patient experiences and outcomes are not always the same.

These differences are often closely related to how treatment is implemented — including whether pre-treatment evaluation is adequate, whether treatment timing is managed appropriately, whether adverse events are identified and treated promptly, and whether long-term management and follow-up remain consistent.

Individually, these factors may seem manageable. In practice, however, they frequently occur simultaneously and influence one another, ultimately shaping the overall treatment course.

At its core, patients are not simply encountering a single technology — they are relying on an entire system of clinical expertise and coordinated care.

 

When Patients Choose Cell Therapy, What Are They Really Choosing?

At the beginning, many patients ask questions such as: “Which technology is newer?” “Which treatment is considered more advanced?” or “Where can this treatment be performed?”

But once the full treatment pathway becomes clear, a more fundamental question emerges: patients are no longer simply evaluating whether the technology exists — they are evaluating who can deliver the entire treatment process more safely, consistently, and systematically.

In other words, what patients are truly choosing is the medical team behind the therapy.

This capability is reflected in multiple areas:

1）Systematic risk assessment and patient stratification

2）Stable treatment coordination and timing

3）The ability to rapidly identify and manage complex complications

4）Ongoing multidisciplinary collaboration

5）Long-term follow-up and post-treatment management

These capabilities may not always be immediately visible, but for patients, they often matter far more than how “new” a technology sounds.

 

How Are These Clinical Capabilities Built Over Time?

No clinical technique or capability emerges overnight. In real-world practice, patients present at different stages of disease and with varying levels of risk, requiring treatment strategies to be continuously adjusted according to individual conditions. These experiences are accumulated gradually through long-term exploration and real-world clinical practice by medical teams.

From pre-treatment risk stratification and evaluation, to decisions regarding bridging therapy and the timing of infusion, to the recognition and management of adverse events during treatment, as well as determining when to initiate multidisciplinary collaboration, every critical step must be repeatedly validated and refined through clinical practice.

At GoBroad, this accumulation of experience is not limited to a single aspect of care, but is reflected throughout the entire treatment pathway. Led by experts such as Director Chunrong Tong, the GoBroad Healthcare Group clinical team was among the earliest in China to carry out cell therapy. To date, GoBroad Healthcare Group has completed more than 6,000 CAR-T treatments. Through treating patients across different disease types and risk profiles, the team has gradually established more mature clinical pathways, while continuously optimizing the integration of pre-treatment evaluation, treatment management, and post-treatment follow-up.

As experience grows, assessment and decision-making for some patients can also begin earlier. For experienced teams, the key is not simply to “treat earlier,” but rather to identify earlier which patients are suitable for this pathway, so that more appropriate decisions can be made at the right time.

It is important to emphasize that this does not mean blindly pursuing “the earlier, the better.” Instead, it is built upon comprehensive evaluation, standardized management, and multidisciplinary judgment, with the goal of ensuring that patients who are truly suitable for treatment can receive the opportunity at the most appropriate stage.

For patients and their families, determining whether a medical team is truly trustworthy should not rely solely on introductions or on whether a hospital “offers the technology.” Experience that truly deserves trust is not something claimed by a single center alone—it is built through long-term clinical practice and validated through broader peer recognition and clinical validation. This is why, for patients, clinical experience, risk management capability, multidisciplinary collaboration, and long-term accumulation of expertise are often far more important than a single technical label.

In recent years, the GoBroad expert team has continued to generate academic contributions in the field of CAR-T therapy. Focusing on clinical innovation in hematologic diseases, optimization of key CAR-T technologies and manufacturing processes, development of risk-stratified evaluation systems, and integration with comprehensive treatment strategies such as hematopoietic stem cell transplantation, CAR-T-related studies from GoBroad have been published in leading international medical journals including Nature Medicine, The Lancet Oncology, Journal of Clinical Oncology, Journal of Hematology & Oncology, and Blood. To date, the team has published more than 60 related papers, with a cumulative impact factor exceeding 600.

At the same time, since 2018, the GoBroad expert team has had more than 300 original research studies selected for presentation at major international conferences such as ASH, ASCO, EHA, and EBMT. Among these, more than 160 studies have been related to CAR-T therapy, including over 40 oral presentations at major congresses. These research outcomes span multiple disease subtypes and therapeutic strategy directions, with findings continuously presented and updated at different stages of development.

These sustained clinical and scientific achievements also provide more visible and objective evidence that this CAR-T team possesses long-term, stable, and systematic treatment capabilities.

 

Why Has GoBroad’s Exploration in the CAR-T Field Continued to Receive International Attention?

In the development of cell therapy, explorations with lasting value are often defined not merely by technological concepts themselves, but by whether they can solve real clinical challenges in complex treatment settings.

In recent years, the GoBroad expert team has continuously advanced cell therapy research across areas including relapsed or refractory hematologic malignancies, autoimmune diseases, and solid tumors. Multiple studies represented globally pioneering advances in clinical exploration and have been consistently published in leading international medical journals and presented at major global academic conferences.

For example, in relapsed or refractory T-cell hematologic malignancies—an internationally recognized therapeutic challenge—the GoBroad expert team led by Director Jing Pan was the first in the world, in 2019, to propose a donor-derived CD7 CAR-T strategy for relapsed/refractory T-ALL/LBL. The team subsequently initiated the world’s first-in-human Phase I trial of CD7 CAR-T therapy for T-ALL, with the results published in the Journal of Clinical Oncology. Building upon this work, the team continued to conduct in-depth research in areas including long-term follow-up, autologous CD7 CAR-T, and allogeneic CD5 CAR-T therapies. Related findings were subsequently published in leading international journals including Nature Medicine, Journal of Hematology & Oncology, Blood, and Journal of Clinical Oncology, opening new therapeutic possibilities for patients with T-ALL.

In the field of relapsed/refractory B-cell hematologic malignancies, the GoBroad expert team led by Director Jing Pan pioneered a stratified CAR-T treatment strategy for B-ALL in 2017. The team carried out systematic research on complication management and efficacy monitoring systems, with related findings published in Leukemia. Subsequently, the team further explored sequential CD19/CD22 CAR-T therapy and, in 2020, became the first to publish clinical data on sequential CAR-T treatment in pediatric relapsed/refractory B-ALL, with results published in Blood. A subsequent prospective Phase II study was later published in The Lancet Oncology. In parallel, the team led by Chunfu Li—one of the most experienced groups in China in terms of TDH transplantation volume and accumulated clinical data—innovatively combined TDH transplantation with CAR-T therapy. This innovative strategy improved treatment outcomes in both pediatric and adult B-ALL patients, while also reducing the incidence of GVHD and contributing to better quality of life.

In the field of relapsed/refractory lymphoma, the GoBroad expert team led by Director Yonghong Zhang was among the early groups to explore sequential infusion strategies using CD19/CD20/CD22 triple-target CAR-T therapy. The team was also the first to report the clinical application of this strategy in pediatric relapsed/refractory Burkitt lymphoma, achieving high remission rates and durable long-term benefits.

In multiple myeloma, expert teams represented by Chun Wang, Yanjing Zhang, and Su Li have long been engaged in cell therapy exploration for relapsed/refractory disease. Their work on novel targets such as BCMA and GPRC5D, as well as dual-target CAR-T treatment strategies, has been repeatedly presented at major international conferences including ASH and EHA.

Beyond hematologic diseases, GoBroad experts have also continued to advance CAR-T clinical exploration in solid tumors. A randomized controlled study of CLDN18.2 CAR-T therapy led by Professor Lin Shen was published in The Lancet, becoming one of the world’s first important randomized controlled studies to demonstrate positive outcomes for CAR-T therapy in solid tumors. Based on these findings, satri-cel (satri-cabtagene autoleucel) was incorporated into the CSCO Guidelines for Gastric Cancer Diagnosis and Treatment (2026 Edition) as part of recommended treatment annotations, making it one of the world’s first CAR-T products for solid tumors to be included in a national clinical practice guideline. This milestone has further advanced the clinical development of CAR-T therapy in solid tumors.

At the same time, the GoBroad CAR-T expert team has continued to expand clinical exploration of CAR-T therapy in autoimmune diseases. In 2026, a Phase I/II study investigating autologous CD19 CAR-T therapy for pediatric and adult systemic lupus erythematosus (SLE) was published in Molecular Therapy, providing preliminary evidence supporting the safety and efficacy of CAR-T therapy in autoimmune diseases.

As these studies continue to attract international attention, citations, and discussion, the GoBroad clinical pathways, risk management systems, and experience in managing highly complex cases reflected behind these achievements are also being increasingly referenced by peers worldwide. This cycle—originating from clinical practice and ultimately returning to clinical application—not only validates these experiences, but also continuously expands their influence. These sustained clinical and scientific accumulations have likewise become an important basis for evaluating whether a team possesses long-term, stable, and systematic treatment capabilities.

 

As Cell therapy Expands Into New Disease Areas, Are the Standards for Evaluation Changing?

As research continues to advance, cell therapy is expanding into more disease areas, including autoimmune diseases and solid tumors. This means that, in the future, more and more patients will encounter it, learn about it, and even seriously consider it as a treatment option. In this process, the standards used to evaluate a therapy are also changing—from simply asking “Does this technology exist?” to asking “Does the team have the ability to implement this technology effectively, consistently, and safely in real clinical practice?”

As the technology itself gradually becomes a baseline requirement, what truly differentiates one team from another is often the depth of long-term clinical experience, the ability to manage highly complex cases, and whether the team has genuinely undergone large-scale, systematic CAR-T clinical practice.

For patients, the real differences experienced during treatment often extend far beyond the cell therapy technology itself. What matters just as much—if not more—are the experience of the clinical team, the quality of process management, the ability to respond to risks and complications, and the strength of long-term follow-up care.

For example, was the pre-treatment evaluation sufficiently thorough? Was the treatment timeline appropriately planned? Could complex situations be identified and managed in a timely manner? Was there continuous management and follow-up after treatment? These aspects may not always appear to be the most “eye-catching,” but they are often the factors that truly influence both the patient experience and treatment outcomes.

For patients, therefore, the increasing standardization of the field is ultimately a positive development. Standardization means that treatment will place growing emphasis on safety, quality, and comprehensive management throughout the entire treatment journey. When making decisions, patients do not need to focus solely on the technology itself. More importantly, they should consider whether a team and hospital are truly capable of managing and delivering the entire treatment journey effectively from beginning to end.

 

Conclusion: When Making a Treatment Decision, What Truly Matters?

This brings us back to the question patients often face at the very beginning: when cell therapy becomes a possible option, the real consideration is no longer simply “Should I do it or not?” More importantly, if a patient chooses this treatment pathway, are the decisions made beforehand truly clear? Can the risks encountered during treatment be properly managed? And after treatment, is there a team that can continue to provide follow-up care and long-term support?

In real-world practice, treatment outcomes are rarely determined by a single moment or step. Rather, they are gradually shaped across multiple interconnected stages throughout the treatment journey. Ultimately, the question of “Can this treatment truly be delivered well?” not only influences clinical outcomes, but is increasingly becoming the most important factor patients need to evaluate when making treatment decisions.

As the technology itself gradually becomes a baseline condition, experience, systematic capabilities, and team expertise are becoming increasingly important. This means that, when patients make choices today, what they truly need to evaluate is not simply whether a treatment is “new,” but whether the treatment pathway is stable, clearly defined, and consistently managed — whether the team can genuinely take responsibility for the entire treatment process, and whether it possesses long-term clinical experience, the ability to manage complex cases, and comprehensive care capabilities throughout the full patient journey.

These are the qualities that deserve greater attention as cell therapy continues to mature.